NES

Across TCGA pan-cancer cohorts, NES mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NES data layer compared with 22 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NES mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NES expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where NES mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.485	0.996	.001	30	view →
PDAC	DFS	Quartile	All	0.844	0.592	.004	23	view →
LSCC	DFS	Median	II,III,IV	0.829	1.000	.003	14	view →
CCRCC	DFS	Tertile	III,IV	0.805	0.392	.002	7	view →
UCEC	OS	Quartile	III,IV	0.346	1.000	.036	4	view →
HNSC	DFS	Tertile	II,III,IV	0.531	0.771	.023	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NES–LUAD (DFS)

Open the LUAD breakdown →